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Background: To understand the relationship between the Staphylococcus aureus infection rate and the reasonable
usage of antibiotics, which will help in the effective control of MRSA infection.
Methods: All data were obtained by the application of the nosocomial infection surveillance network. Drug
resistance, departmental sources, and isolated sites as well as infection rate variations of S. aureus were analyzed in
the 7-year period in key departments.
Results: Between 2008 and 2014, 2525 strains of S. aureus isolates, mainly from sputum, skin/soft tissue,
bloodstreams were collected from several hospital departments including respiratory, burn, brain surgery,
orthopedics, ICU, and emergency. During these periods, the resistance rate of S. aureus to most drugs, including
oxacillin, tetracycline, erythromycin, clindamycin, gentamicin, and ciprofloxacin, showed a tendency to decrease.
The resistance to sulphamethoxazole/trimethoprim showed the opposite trend (P = 0.075) and there were no S.
aureus strains resistant to linezolid and vancomycin. The MRSA infection rate was different across crucial hospital
departments, with the burns department and ICU maintaining a high infection level. Over the 7-year period, both
the brain surgery and the emergency departments had an expected upward trend (P < 0.05), while the orthopedic
department showed a clear downward trend (P < 0.05) in MRSA infection rate.
Conclusion: Hospitals should continue to maintain the current pattern of antibiotic administration, while more
effective measures should be taken to reduce the high MRSA infection rate in some important hospital departments.
Keywords: S. aureus, Drug resistance, Trend, ChinaBackground
Staphylococcus aureus (S. aureus) is one of the most
common clinical pathogens, causing nosocomial and
community-acquired infections [1, 2]. Since methicillin-
resistant S. aureus (MRSA) was first discovered, MRSA
has now quickly become a predominant infectious patho-
gen with increasing global prevalence [3, 4]. Because of
higher drug-resistance rate, MRSA is more difficult to
treat, requires longer hospitalization periods, and results
in higher morbidity and mortality than methicillin-
susceptible S. aureus (MSSA) [5]. According to data from
the U.S. Centers for Disease Control and Prevention
(CDC), the number of severe MRSA infections in 2012* Correspondence: chenks100@126.com
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MRSA was renamed “super bug” [6]. In order to achieve
better treatment and prognosis, it is paramount to find
and adopt measures to control MRSA infection. In terms
of pathogenicity, S. aureus infection is characterized by
different virulence and drug resistance [7, 8]. While viru-
lence is an inherent characteristic of each S. aureus strain,
the degree of drug resistance is mainly affected by medical
activities, such as prescribing habits, hospitalization pe-
riods, and hospital environment [9]. Studies have shown
that changes in the bacteria environment was the main
reason for the appearance of drug-resistant strains, and
not the uneven distribution of infections across different
hospitals or wards [10, 11]. In recent years, owing to the
broad application of antibiotics in hospital as well as self-
medication in communities in China, bacteria drug-le is distributed under the terms of the Creative Commons Attribution 4.0
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the Chinese Health Ministry to issue guidelines for a better
use of antimicrobial drugs in hospitals. It is therefore ne-
cessary to assess the effects of these guidelines in different
hospitals, to understand whether these regulations are ef-
fective. Here, for the first time we report the trend of S.
aureus infection rate in different key departments of a gen-
eral tertiary-care teaching hospital after these regulations
were put in place. These findings might provide some valu-
able information to local clinicians for selecting the appro-
priate antibiotic against S. aureus, and to health public
departments offering more effective treatment measures.
Methods
Setting and study design
The hospital of Nanchang University is a large, general
tertiary-care teaching hospital and regional medical center
with 3,500 beds, located in the southeast region of China.
The hospital includes almost all departments, such as
burns, brain surgery, orthopedics, respiratory, pediatrics,
gynecology and obstetrics, hematology and oncology,
emergency room, and intensive care unit (ICU).
All records from the Hospital Information Warehouse,
Clinical Microbiology Laboratory, and Pharmacy Depart-
ment, were retrospectively collected at yearly intervals
by two researchers, to obtain hospital-wide population-
level data. The data include almost all bacteria strains
and information on antimicrobial resistance. For some
important pathogens, such as S. aureus, more detailed
information, including different isolated rates and drug
susceptibility in key departments, was present.
Recently, the Chinese Ministry of Health issued several
documents to promote the correct usage of antibiotics
in recent years. The aim of this study is to understand
the relationship between the trend of isolated rate and
antimicrobial resistance of S. aureus according to the
current pattern of antibiotic administration.
Microbiology data
Different strains of S. aureus were identified using the
VITEK-2 automated system (bioMérieux Inc., France).
The same system was used to measure susceptibility to
the antibiotics routinely tested (penicillin G, oxacillin,
gentamicin, ciprofloxacin, clindamycin, erythromycin, tetra-
cycline, linezolid, vancomycin, and sulphamethoxazole/tri-
methoprim). The drug susceptibility results were compared
to the newest standard of the Clinical and Laboratory Stan-
dards Institute (CLSI) [13]. Strains showing resistance to
oxacillin were defined as MRSA, as described in the manu-
facturer’s instructions. All S. aureus-positive clinical speci-
mens (sputum, skin/soft tissue, blood fluid, etc.) obtained
from the hospital in the period between January 2008 and
December 2014, were included in the analysis (identical
strains derived from the same patient were excluded). Thereference strains used for S. aureus were ATCC25923 and
ATCC29213.
Statistical analysis
Univariate analysis was used to determine the difference
in drug resistance levels between MRSA and MSSA
strains. A chi-square test was used to evaluate the differ-
ence in categorical variables. Variation analyses of S.
aureus drug-resistant rate were performed using SPSS
17.0 (Statistical Product and Service Solutions, SPSS Inc.,
USA). Statistical significance was defined as P < 0.05.
Results
Distribution of the isolated S. aureus strains
During the 7-year period (January 2008-December
2014), a total of 2,525 strains of S. aureus were isolated
from different patients admitted to various hospital
wards. Among those, 967 (38.3%, 967/2525) were recov-
ered from sputum, 713 (28.2%, 713/2525) from blood
samples, 411 (16.3%, 411/2525) from skin/soft tissue,
249 (9.9%, 249/2525) from other sterile body fluids, and
185 from other organ. 1223 (48.4%, 1223/2525) isolated
strains were classified as MRSA by system assay. The
amount of isolated S. aureus strains differed across the
departments; respiratory had 411(16.3%, 411/2525), burn
319 (12.6%, 319/2525), brain surgery 235 (9.3%, 235/
2525), orthopedics 201 (8.0%, 201/2525), emergency 191
(7.6%, 191/2525), and ICU 168 (6.6%, 168/2525). The
other departments including pediatrics, infectious, and
hematology, had much lower levels of S. aureus strains.
Trend of drug-resistance rate between 2008 and 2014
As shown in Table 1, amongst all the drugs tested, penicil-
lin G was the one to which most strains showed resistance
to (97.6% (205/210) in 2008 and 73.7% (469/636) in 2014),
while erythromycin ranked second (81.9% (172/210) in
2008 and 54.7% (348/636) in 2014). Not many S. aureus
isolates were resistant to sulphamethoxazole/trimethoprim
(17.1% (359/2525) in 2008 and 23.6% (596/2525) in 2014).
All isolates were sensitive to linezolid and vancomycin.
Trend analysis showed that S. aureus resistance to oxacil-
lin, gentamicin, ciprofloxacin, clindamycin, erythromycin,
and tetracycline significantly decreased over time (P < 0.05)
(Table 1). The percentage of strains resistant to penicillin
G showed a decreasing tendency, although the observed
change was not significant (P = 0.127). The percentage of
strains resistant to sulphamethoxazole/trimethoprim fluc-
tuated, with an overall increasing trend (P = 0.075).
Trend of drug resistance rate in key departments
Because doctors in different departments have different
habits and criteria for antibiotic usage, it was necessary
to determine the drug-resistance situation in each de-
partment. Hence, we selectively analyzed the drug-
Table 1 Trend of drug-resistance rate at the first affiliated hospital of Nanchang University, 2008-2014
Year (N) Penicillin G Oxacillin Gentamicin Ciprofloxacin Clindamycin Erythromycin Linezolid Vancomycin Tetracycline Cotrimoxazole
2008 (210) 97.6 69.5 60.5 64.3 75.2 81.9 0 0 69.5 17.1
2009 (259) 96.5 58.3 47.5 59.1 67.6 74.9 0 0 63.3 16.6
2010 (257) 93.4 50.2 50.6 59.1 63.8 68.1 0 0 59.9 19.1
2011 (273) 91.9 67.4 42.1 50.2 59.7 68.9 0 0 54.9 24.9
2012 (399) 91.2 49.6 39.1 52.4 52.1 66.9 0 0 38.3 25.1
2013 (491) 91.2 48.3 40.1 52.1 53 4 60 1 0 0 49.3 13.4
2014 (636) 73.7 42.1 30.8 31.8 32.5 54.7 0 0 34.0 23.6
Time series analysis model
Slope (β) −2.323 −9.507 −7.285 −7.909 −7.365 −7.127 … … −7.815 3.160
P-value 0.127 0.002 0.007 0.005 0.007 0.008 … … 0.005 0.075
Trend Decreasing Decreasing Decreasing Decreasing Decreasing Decreasing … -… Decreasing Increasing
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orthopedics, and emergency departments as well as in the
ICU (Table 2). As shown in Appendix 1, the resistance in-
cidence to almost all selected antibiotics (except for linez-
olid and vancomycin) had a decreasing trend during the
7-year period. On the other hand, the resistance rate to
sulphamethoxazole/trimethoprim slightly increased. Based
on the results collected, we found that the resistance rate
of MRSA was usually higher than that of MSSA (Table 3).
Because MRSA is an important pathogen and indicates a
higher risk of contracting S. aureus infection [14], it was ne-
cessary to analyze the variation in MRSA infection fre-
quency in key hospital departments during the same 7-year
period. As shown in Fig. 1, MRSA infection was maintained
at high levels in the burns department and ICU over the 7-
year period; brain surgery and the emergency departmentTable 2 Antimicrobial susceptibility trend of S. Aureus in key hospita
Period (N) Penicillin G Oxacillin Gentamicin Ciprofloxacin Clindamyc
Respiratory Dept (411)
X2 value 0.59 3.07 3.88 4.46 3.14
P value 0.44 0.08 0.05 0.04 0.08
Bum Dept (319)
X2 value 8.53 3.26 8.72 11.94 10.00
P value 0.00 0.07 0.00 0.00 0.00
Brain surgery (235)
X2 value 1.33 6.41 4.71 6.89 5.30
P value 0.25 0.01 0.03 0.01 0.02
Orthopedics (201)
X2 value 1.19 4.14 4.86 6.72 7.61
P value 0.28 0.04 0.03 0.01 0.01
Emergency Dept (191)
X2 value 3.13 6.97 5.68 6.86 5.88
P value 0.08 0.01 0.02 0.01 0.02
ICU (168)
X2 value 0.83 1.84 2.74 2.31 1.81
P value 0.36 0.18 0.10 0.13 0.18showed an increased MRSA infection rate over time (P <
0.05), while both the respiratory and orthopedics depart-
ments had a decreasing trend, although the former did not
attain statistical significance (P = 0.08 and 0.04, respectively).
Additionally, the ratio of MRSA and MSSA isolates
changed over time. Although the incidence of MRSA
isolates was higher than that of MSSA in the period be-
tween 2008 and 2012, it decreased in the following years,
reaching less than 40% in 2014 (Fig. 2).
Discussion
As a major human pathogen, S. aureus causes a wide range
of infections, such as lung disease, bacteremia, infectious
endocarditis, as well as skin/soft tissue, and osteoarticular
and device-related infections [15]. The epidemiological
characteristics of S. aureus, especially MRSA, changel departments, 2008–2014
in Eiythromycin Linezolid Vancomycin Tetracycline Cotrimoxazole
1.35 – – 3.94 0.91
0.24 – – 0.05 0.34
10.24 – – 9.39 5.97
0.00 – – 0.00 0.02
4.87 – – 6.48 1.64
0.03 – – 0.01 0.20
8.71 – – 8.22 1.92
0.00 – – 0.00 0.17
5.48 – – 5.05 2.44
0.02 – – 0.02 0.12
1.97 – – 3.62 2.49
0.16 – – 0.06 0.12
Table 3 Antimicrobial susceptibility and isolated rates (%) of MRSA and MSSA in key departments
Period (N) Penicillin G Oxacillin Gentamicin Ciprofloxacin Clindamycin Erythromycin Linezolid Vancomycin Tetracycline Cotrimoxazole
Respiratory Dept (411)
MRS A (190) 100.0 100.0 64.7 75.3 83.7 94.2 0 0 64.7 16.8
MSSA (221) 79.2 0.0 24.9 40.3 49.3 70.1 0 0 40.3 8.1
OR 0.79 – 0.38 0.23 0.59 0.74 – – 0.62 0.49
95%CI 0.59–1.06 – 0.26–0.57 0.16–0.34 0.43–0.81 0.55–1.00 – – 0.44–0.88 0.25–0.92
P value 0. 10 – 0.00 0.00 0.00 0.05 – – 0.00 0.02
Bum Dept (319)
MRS A (296) 100.0 100.0 48.6 55.4 56.8 188 0 0 47.0 26.7
MSSA (23) 34.8 0.0 17.4 56.5 47.8 52.2 0 0 52.2 21.7
OR 0.35 – 0.45 0.24 0.84 0.82 – – 1.11 0.81
95%CI 0.13–0.82 – 0.11–1.36 0.04–0.80 0.36–1.86 0.36–1.77 – – 0.49–2.41 0.23–2.29
P value 0.01 – 0.14 0.01 0.65 0.59 – – 0.78 0.69
Brain surgery (235)
MRSA (150) 100.0 100.0 50.7 84.7 80.7 80.7 0 0 88 38
MSSA (85) 85.9 0.0 25.9 25.9 30.6 43.5 0 0 27 5
OR 0.86 – 0.51 0.30 0.38 0.54 – – 0.54 0.23
95%CI 0.57–1.29 – 0.28–0.90 0.17–0.53 0.22–0.64 0.33–0.87 – – 0.31–0.92 0.07–0.62
P value 0.44 – 0.01 0.00 0.00 0.01 – – 0.02 0.00
Orthopedics (201)
MRSA (75) 100.0 100.0 93.3 86.7 64.0 65.3 0 0 42 27
MSSA (126) 85.4 0.0 29.4 41.3 41.3 44.4 0 0 54 13
OR 0.85 – 0.31 0.48 0.64 0.68 – – 0.76 0.29
95%C1 0.55–1.31 0.19–0.53 0.29–0.78 0.38–1.08 0.41–1.13 – – 0.45–1.30 0.13–0.62
P value 0.44 – 0.00 0.00 0.08 0.11 – – 0.29 0.00
Emergency Dept (191)
MRSA (90) 100.0 100.0 55.6 67.8 70.0 71.1 0 0 62 19
MSSA (101) 61.4 0.0 32.7 32.7 40.6 53.5 0 0 52 17
OR 0.61 – 0.59 0.48 0.58 0.75 – – 0.75 0.80
95%CI 0.39–0.96 – 0.34–1.02 0.28–0.83 0.35–0.97 0.46–1.22 – – 0.46–1.22 0.36–1 73
P value 0.03 – 0.05 0.01 0.03 0.22 – – 0.22 0.53
ICU (168)
MRSA (131) 100.0 100.0 39.7 79.4 92.4 83.2 0 0 83 51
MSSA (37) 81.1 0.0 18.9 45.9 27.0 43.2 0 0 14 4
OR 0.81 – 0.48 0.34 0.29 0.52 – – 0.60 0.28
95%CI 0.45–1.44 – 0.17–1.18 0.14–0.74 0.12–0.63 0.26–1.02 – – 0.28–1.22 0.07–0.84
P value 0.44 – 0.09 0.00 0.00 0.04 – – 0.13 0.01
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the treatment of penicillin-resistant S. aureus infection in
1959, methicillin-resistant strains emerged immediately
afterwards, becoming one of the most important strains
worldwide during the following decades [16]. Furthermore,
people with MRSA infection are 64.0% more likely to die
than people with MSSA infection, hence increasing the
cost of health care due to lengthier stays in hospital and
more intensive care [17]. It is therefore necessary to adopt
new measures to decrease the MRSA infection frequency.
Kim et al. [18] studied the trend of MRSA infection, find-
ing that a method for decreasing the frequency of infectionis a more reasonable use of antibiotics. In the present
study, we showed that the isolated rate of MRSA decreased
over a period of 7 years, from 69.5% (146/210) in 2008 to
42.1% (268/2525) in 2014 (P < 0.05). Although the actual
reasons for the decrease are not known, it is likely that this
is owing to the improved measures for antibiotic adminis-
tration (Appendix 2). Indeed, in 2008, the Chinese Ministry
of Health issued the “Notice on the relevant issues con-
cerning the clinical application management of antibiotics”
document. Moreover, in 2009, the Ministry contacted ex-
perts to reexamine the antibiotic prescriptions in order to
achieve a more reasonable antibiotic usage in some tertiary
Fig. 1 Dynamics of MRSA infection frequency in key departments of the first affiliated hospital of Nanchang University, 2008–2014. MRSA
infection frequency (ratio) is presented on the y-axis
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proved in the following years. For example, according to
statistics from the pharmacy department in our hospital,
the percentage of prophylactic antibiotics used to prevent
infections in surgical aseptic operations significantly de-
creased from 73.4% (11056/15063) in 2008 to 33.3% (1272/
38195) in 2014, and the rate of reasonable use of antibi-
otics increased from 44.50% (6703/15063) to 90.85%
(3470/38195). Subsequently, the rate of rational use of anti-
biotics has been maintained at more than 90.0%, in line
with the national relevant requirements. The Ministry of
Health issued the “Clinical application of antibacterial
drugs Management method” in 2012 and developed special
protocols to alter the current use of antimicrobial drugs,
which provided guidance for standard antibiotic usage,
resulting in an even more reasonable use of antibiotics.
Our results were consistent with studies supporting the
idea that a rational use of antibiotics, particularly broad-Fig. 2 Frequency (no. of isolates) of MRSA and MSSA isolated at the
first affiliated hospital of Nanchang University, China, 2008–2014spectrum antibiotics, can effectively reduce S. aureus drug-
resistance rate [19, 20].
Despite the fact that MRSA had a higher resistant rate
than MSSA, the infectious situation varied in different
departments. In order to propose a better differential
treatment, it was necessary to determine S. aureus infec-
tion rate in different departments.
According to the data collected from important hospital
departments, we found that the MRSA isolated rate in
both the burns department and ICU was maintained above
80%. This was probably owing to the fact that most pa-
tients in these two departments are seriously ill and need
effective treatments; hence, broad-spectrum antibiotics are
usually prescribed [21]. For example, vancomycin, cefoper-
azone/sulbactam, and ketoconazole are usually prescribed
to treat severe burn patients in hospitals. Antibiotic usage
in ICU had no limitations. Moreover, the majority of pa-
tients in these departments have long-term hospitalization
and are immune-compromised, which usually lead to per-
sistent infection and an excessive use of antibiotics [22].
The MRSA infection frequency in the brain surgery and
emergency departments increased in the 7-year period, op-
posite to the overall trend in other departments. The most
plausible reason was that some departments, such as brain
surgery, emergency, internal medicine, etc., had established
independent ICU wards, owing to the expansion of the
hospital (from a capacity of 1,600 beds to 3,500 beds) in
2012. The respiratory and especially the orthopedics de-
partment displayed a decreasing trend throughout the
years, perhaps because of a more strict usage of antibiotics.
The results of our study cannot be generalized because
the analysis of the small number of isolated strains in
some departments does not reach statistical significance
for some antibiotics tested. We also did not know the
antibiotic usage of each individual patient. Therefore, we
Chen et al. BMC Infectious Diseases  (2017) 17:97 Page 6 of 8do not have enough data to prove the relationship be-
tween sensible antibiotic usage and decreased S. aureus
drug-resistance. Since the antibiotic prescription habit
was the only factor that changed, we believe that the
more strict usage of antibiotics is responsible for the de-
crease in drug-resistant strains. Through the rational use
of antibiotics, the frequency and drug-resistance rate of
MRSA infection showed a downward trend.
In contrast, most gram-negative bacteria still show high
levels of drug-resistance. For instance, K. pneumoniae
showed a rising resistance trend, in contrast to what isTable 4 The infectious rate and trend in S.aureus in key department
Period (N) Penici llin G Oxa cillin Genta micin Ciprof loxacin Clinda myc
Respiratory Dept (411)
2008(50) 100.0 70.0 60.0 76.0 84.0
2009(52) 98.1 59.6 51.9 71.2 75.0
2010(41) 95.1 46.3 53.7 63.4 75.6
2011(52) 92.3 32.7 44.2 55.8 65.4
2012(49) 91.8 14.3 38.8 53.1 53.1
2013(71) 84.5 40.8 39.4 43.7 62.0
2014(96) 75.0 35.4 30.2 51.0 54.2
χ2 value 0.59 3.07 3.88 4.46 3.14
P value 0.44 0.08 0.05 0.04 0.08
Burn Dept (319)
2008(11) 100.0 90.9 45.4 54.5 81.8
2009(26) 100.0 92.3 38.5 50.0 80.8
2010(31) 100.0 90.3 41.9 54.8 67.7
2011(43) 100.0 95.3 46.5 48.8 62.8
2012(45) 95.6 88.9 26.7 48.9 60.0
2013(73) 94.5 93.2 30.1 53.4 49.3
2014(96) 90.6 89.6 37.5 50.0 39.6
χ2 value 8.53 3.26 8.72 11.94 10.00
P value 0.00 0.07 0.00 0.00 0.00
Aural surgery (235)
2008 (27) 100.0 48.1 51.8 70.4 81.5
2009 (24) 95.8 54.2 66.7 70.8 79.2
2010 (22) 95.4 59.1 40.9 63.6 59.1
2011 (31) 96.8 64.5 35.5 64.5 61.3
2012 (37) 97.3 70.3 40.5 56.8 62.2
2013 (41) 92.7 70.7 36.6 61.0 56.1
2014 (54) 88.9 66.7 33.3 61.1 51.9
χ2 value 1.33 6.41 4.71 6.89 5.30
P value 0.25 0.01 0.03 0.01 0.02
Orthopedics(201)
2008 (23) 100.0 65.2 60.9 56.5 52.2
2009 (21) 95.2 52.4 47.6 47.6 42.9
2010(21) 90.5 38.1 52.4 66.7 71.4
2011 (26) 92.3 38.5 53.8 69.2 53.8
2012 (28) 89.3 25.0 35.7 57.1 39.3
2013 (35) 88.6 37.1 42.9 62.9 54.3
Appendix 1reported in the literature [23]. The opinion that a more ra-
tional antibiotic usage could decrease resistance does not
apply to gram-negative bacilli. Whether there are some
other factors leading to the high rate of antibiotic resist-
ance still needs to be analyzed.
Conclusion
S.aureus is an important pathogen. The drug-resistance
dynamics showed that reasonable usage of antibiotics
has huge valuable for decreasing the MRSA infectious
rate in a teaching hospital, China.s
in Erythro mycin Line zolid Vanco mycin Tetracy cline Cotrim oxazole
94.0 0 0 82.0 10.0
84.6 0 0 63.5 9.6
90.2 0 0 53.7 19.5
84.6 0 0 46.2 13.5
83.7 0 0 42.9 10.2
76.1 0 0 49.3 9.9
70.0 0 0 37.5 13.5
1.35 – – 3.94 0.91
0.24 – – 0.05 0.34
90.9 0 0 63.6 27.3
76.9 0 0 76.9 26.9
71.0 0 0 54.8 29.0
67.4 0 0 55.8 32.6
60.0 0 0 48.9 26.7
57.5 0 0 38.4 20.5
52.1 0 0 34.4 25.0
10.24 – – 9.39 5.97
0.00 – – 0.00 0.02
85.2 0 0 63.0 11.1
79.2 0 0 58.3 12.5
72.7 0 0 54.5 22.7
67.7 0 0 51.6 19.3
59.4 0 0 45.9 16.2
61.0 0 0 43.9 22.0
53.7 0 0 38.9 20.4
4.87 – – 6.48 1.64
0.03 – – 0.01 0.20
56.5 0 0 60.9 17.4
47.6 0 0 47.6 14.3
61.9 0 0 52.4 28.6
57.7 0 0 50.0 26.9
42.9 0 0 42.9 17.9
54.3 0 0 48.6 17.1
Table 4 The infectious rate and trend in S.aureus in key departments (Continued)
2014 (47) 83.0 30.0 27.7 51.0 44.7 48.9 0 0 40.4 19.1
χ2 value 1.19 4.14 4.86 6.72 7.61 8.71 – – 8.22 1.92
P value 0.28 0.04 0.03 0.01 0.01 0.00 – – 0.00 0.17
Emergency Dept (191)
2008 (20) 95.0 60.0 65.0 65.0 80.0 85.0 0 0 85.0 15.0
2009 (17) 94.1 52.9 52.9 52.9 70.6 76.5 0 0 64.7 17.6
2010 (22) 81.8 63.6 68.2 63.6 68.2 77.3 0 0 72.7 18.2
2011 (21) 81.0 57.1 57.1 57.1 61.9 71.4 0 0 81.0 23.8
2012 (24) 75.0 41.7 50.0 37.5 50.0 62.5 0 0 62.5 25.0
2013 (32) 75.0 62.5 40.6 46.9 46.9 50.0 0 0 53.1 18.8
2014 (55) 69.1 58.2 32.7 40.0 38.2 45.5 0 0 38.2 16.4
χ2 value 3.13 6.97 5.68 6.86 5.88 5.48 – – 5.05 2.44
P value 0.08 0.01 0.02 0.01 0.02 0.02 – – 0.02 0.12
ICU(168)
2008 (18) 100.0 88.9 50.0 83.3 88.9 88.9 0 0 83.3 38.9
2009(24) 100.0 75.0 29.2 75.0 70.8 79.2 0 0 75.0 33.3
2010 (16) 100.0 81.2 50.0 93.8 87.5 68.8 0 0 62.5 43.8
2011(21) 95.2 76.2 47.6 81.0 85.7 66.7 0 0 66.7 42.9
2012(17) 100.0 70.6 35.3 47.1 70.6 58.8 0 0 41.2 35.3
2013(28) 92.9 82.1 32.1 75.0 78.6 82.1 0 0 50.0 28.6
2014(44) 90.9 72.7 25.0 61.4 72.7 72.7 0 0 43.2 22.7
χ2 value 0.83 1.84 2.74 2.31 1.81 1.97 – – 3.62 2.49
P value 0.36 0.18 0.10 0.13 0.18 0.16 – – 0.06 0.12
Table 5 Relative antibiotics usage regulation issued by Ministry of Health of China
Time URL; Content; Key points
Jan-28 − 2008 http://www.nhfpc.gov.cn/zhuzhan/wsbmgz/201304/53cdeec6d8f4461583296ab59bf1fb93.shtml. Content: Notice on strengthening
the price management of medical institutions to control the unreasonable growth of medical expenses. Key points: Regulate the
behavior of medical services, and encourage the use of low-cost drugs.
Apr-15–200 http://www.nhfpc.gov.cn/zhuzhan/wsbmgz/201304/9a70b1ec336846f8b3858262c8ed6e29.shtml. Content: Notice on further
strengthening the management of clinical application of antibacterial drugs. Key points: 1. Strengthen the management of
perioperative antimicrobial prophylaxis and application; 2. To strengthen the management of clinical application of
fluoroquinolones; 3. In strict accordance with the provisions of the management system for the classification of antimicrobial drugs,
strengthen the management of clinical application of antibiotics; 4. To strengthen the guidance and supervision of clinical
application of antibacterial drugs and strengthen the guidance and supervision of clinical application of antibacterial drugs
Jul-15–2008 http://www.nhfpc.gov.cn/zhuzhan/wsbmgz/201304/caa37dae8bde44bc9a42dd10aeb9ff43.shtml. Content: Notice on strengthening the work
of hospital infection control in multi- drug resistant bacteria. Key points: 1. Management of nosocomial infection in multiple drug resistant
bacteria; 2. To establish and improve the monitoring of multi-drug resistant bacteria; 3. Prevention and control of the spread of multi-drug re-
sistant bacteria; 4. Strengthen the rational use of antibacterial drugs;5. Strengthen education and training of medical personnel.
Mar-25–2009 http://www.nhfpc.gov.cn/zhuzhan/wsbmgz/201304/0bf024050b7c4f229bc3e49f75f1e0da.shtml. Content: Notice on the relevant issues
concerning the clinical application of antimicrobial agents. Key points: 1. In order to strictly control the surgical treatment of type I incision
and to strengthen the management of prophylactic application of antibiotics in perioperative period; 2. Strict control of the clinical
application of fluoroquinolones; 3. Strict implementation of the management system of antimicrobial drugs; 4. To strengthen the monitoring
of clinical microbiology and bacterial resistance, establish the early warning mechanism for the clinical application of antibacterial drugs.
May-7 − 2013 http://www.nhfpc.gov.cn/yzygj/s3585u/201305/823b9d131ff4416ab7b41b2c4e1f0e83.shtml. Content: Notice on further development
of the special rectification activities of national antimicrobial drugs. Key words : 1. To clarify the clinical application management
responsibility system; 2. Investigation of clinical application of antimicrobial agents; 3. Establishment of a technical support system for
clinical application of antibacterial drugs; 4. Strict implementation of the management system of antimicrobial drugs; 5. To establish a
system for the selection and evaluation of antimicrobial agents, and to strengthen the management of antimicrobial agents; 6. Increase
the clinical application of antimicrobial drugs related indicators control efforts; 7. Surveillance and evaluation of clinical application of
antimicrobial agents; 8. Strengthen the detection and monitoring of bacterial resistance in clinical microbiology; 9. Strict management of
drug prescribing authority and the qualification management of drug in the drug of the pharmacist; 10. Improve the management and
reward system of antibacterial drugs, and seriously investigate and deal with the irrational use of antibacterial drugs; 11. Establish and
improve the clinical application of antimicrobial agents and bacterial resistance monitoring network.
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